leisure time -WSS

leisure time

author：comprehensive 2025-08-23 08:54:26 - browse：4768

Photo illustration of Fyodor Urnov surrounded by DNA strands. -- health coverage from STAT — Christine Kao/STAT

Researchers attending gene therapy meetings over the past couple years were liable to bump into a svelte, graying scientist explaining in emphatic, Russian-inflected English that the U.S. was wasting the grand potential of CRISPR gene editing.

Fyodor Urnov, the scientist in question, estimates he gave the talk 30 to 40 times: to fellow researchers, pharma executives, Food and Drug Administration officials, congressional staff, journalists, patient advocates. “Anyone who would listen,” he says.

The problem was one of scale. Sure, for-profit companies were developing cures for a small handful of genetic diseases, such as sickle cell disease. But there were hundreds of devastating conditions that CRISPR might be able to cure but that no entity was seriously working on.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： In Spain, a hospital brews its own CAR

WSS

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Keeping primary care docs in field isn't impossible, says AAFP CEO

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Grail spinoff by Illumina should end disastrous merger attempt

How to increase colonoscopy rates? Looks like an AI can help

FDA's Pazdur wants cancer trials to range beyond China alone

knowledge

leisure time

hotspot

Jerome Adams on the need for new antivirals for Covid

Cord blood banking comes at a high cost to babies

23andMe had bad news about my health. I wish a person had delivered it

Kaiser's Risant Health gobbled up Geisinger. Who is next?

How one medical school became remarkably diverse

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Why health records don't always know when patients are dead

Trump demands the U.S. pay no more for drugs than other countries … again

HCA sued by state AG for quality issues at Mission Health

entertainment

Medicare Advantage beneficiaries sue Humana over algorithm use

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Grail spinoff by Illumina should end disastrous merger attempt

Medicare Advantage beneficiaries sue Humana over algorithm use

Three trends to watch in biotech in 2024

Let's speed up science by embracing open access publishing

knowledge

focus

Wikipedia

knowledge